Clinical Trial Update: Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating intraperitoneal injection of oncolytic virus H101 for refractory malignant ascites has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• H101 (oncolytic adenovirus H101)

Snippet

Sponsor: Fudan University | Conditions: Refractory Malignant Ascites | Phase 2 | Status: COMPLETED